期刊文献+

硼替佐米对骨髓瘤细胞株RPMI8226增殖和凋亡影响的研究 被引量:2

Study of the effect of bortezomib on the proliferation and apoptosis of multiple myeloma cell line RPMI8226
下载PDF
导出
摘要 目的探讨硼替佐米对骨髓瘤细胞株RPMI8226增殖和凋亡的影响。方法采用20、40、60、80和100 nmol/L的硼替佐米处理骨髓瘤细胞株RPMI8226(处理组),以不含硼替佐米的细胞作为对照(对照组)。采用MTT法检测硼替佐米对RPMI8226细胞的增殖抑制作用,采用Annexin V-FITC/PI流式细胞术检测细胞凋亡率,采用RT-PCR和Western Blot技术检测细胞Wnt/β-catenin信号通路相关蛋白β-catenin、c-myc及PI3K/AKT信号通路相关蛋白Bcl-2、Bax的mRNA和蛋白表达水平。结果不同浓度的硼替佐米均可抑制RPMI8226细胞的增殖,且呈剂量效应;20、40、60、80和100 nmol/L硼替佐米处理组的RPMI8226细胞凋亡率分别为(11.80±0.56)%、(19.45±1.25)%、(36.82±2.26)%、(43.56±3.50)%和(56.62±5.02)%,均高于对照组的(8.02±0.45)%,差异均有统计学意义(P﹤0.05)。处理组c-myc、β-catenin及Bcl-2的mRNA和蛋白表达水平均低于对照组,且随硼替佐米浓度的增加而下降;而Bax的mRNA和蛋白表达水平均高于对照组,且随硼替佐米浓度的增加而升高。结论硼替佐米可抑制多发性骨髓瘤细胞的增殖,促进其凋亡,作用机制可能与调控Wnt/β-catenin信号通路和PI3K/AKT信号通路有关。 Objective To explore the effects of bortezomib on the proliferation and apoptosis of multiple myeloma(MM) cell line RPMI8226.Method 20,40,60,80 and 100 nmol/L of bortezomib were used to treat the MM cell line RPMI8226 as 5 treatment groups,respectively,and blank cell line not containing bortezomib was set as control.MTT assay was utilized to detect the inhibition of bortezomib on RPMI8226,Annexin V-FITC/PI flow cytometry was applied to detect cell apoptosis rate,besides,the m RNA and protein expression of Wnt/β-catenin signaling pathway related proteinβ-catenin,c-myc and PI3K/AKT signaling pathway related protein Bcl-2 and Bax were determined by RT-PCR and Western Blot.Result Bortezomib at any concentration could inhibit the proliferation of RPMI8226 cells,presenting a dosedependent effect; after treatment with the different bortezomib concentrations of 20,40,60,80 and 100 nmol/L,the apoptosis rate of RPMI8226 cells were(11.80±0.56)%,(19.45±1.25)%,(36.82±2.26)%,(43.56±3.50)% and(56.62±5.02)%,respectively,and all were higher than that in the control group at(8.02±0.45)%,with statistically significant difference observed(P〈0.05); the m RNA and protein expression of c-myc,β-catenin and Bcl-2 in all bortezomib-treated groups were lower than that in control group,and higher inhibition was observed as the concentration of bortezomib increased; while the Bax m RNA and protein expression was higher than that in control group,and increased along with the elevation of bortezomib concentration.Conclusion Bortezomib can inhibit the proliferation of the MM cells,promoting its apoptosis,which may be related to the inhibition of Wnt/β-catenin signaling pathway and PI3K/AKT signal pathway.
作者 李录克 时艳荣 赵文华 LI Luke, SHI Yanrong, ZHAO Wenhua(Department of Hematology, General Hospital of Shenma Medical Group, Pingdingshan 467000, He' nan, Chin)
出处 《癌症进展》 2018年第1期28-31,共4页 Oncology Progress
关键词 硼替佐米 多发性骨髓瘤 增殖 凋亡 信号通路 bortezomib multiple myeloma proliferation apoptosis si^aling pathways
  • 相关文献

参考文献13

二级参考文献195

  • 1谭亚敏,黄河.硼替佐米治疗多发性骨髓瘤临床应用进展[J].肿瘤学杂志,2006,12(4):342-344. 被引量:11
  • 2李超,伏圣博,刘华玲,马欣荣.细胞凋亡研究进展[J].世界科技研究与发展,2007,29(3):45-53. 被引量:74
  • 3杨升,卢辉山.Wnt信号通路与消化道肿瘤关系的研究进展[J].世界华人消化杂志,2007,15(27):2880-2884. 被引量:14
  • 4Traynor K. Pomalidomide approved for multiple myeloma [J]. Am J Health Syst Pharm, 2013, 70: 474. 被引量:1
  • 5Latif T, Chauhan N, Khan R, et al. Thalidomide and its analogues in the treatment of Multiple Myeloma[J]. Exp Hematol Oncol, 2012, 1: 1- 8. 被引量:1
  • 6Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma ceils to conventional therapy[J]. Blood, 2000, 96: 2943-2950. 被引量:1
  • 7Gorgun G, Calabrese E, Soydan E, et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma [J]. Blood, 2010, 116: 3227-3237. 被引量:1
  • 8Bolzoni M, Storti P, Bonomini S, et al. Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules [J]. Exp Hematol, 2013, 41: 387-397. 被引量:1
  • 9Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSDl-mediated epigenetic mechanism[J]. Cancer Res, 2009, 69: 7347-7356. 被引量:1
  • 10Mitsiades N, Mitsiades CS, Poulaki V, et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications[J]. Blood, 2002, 99: 4079-4086. 被引量:1

共引文献202

同被引文献30

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部